BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 16741551)

  • 1. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
    Paumgartner G; Beuers U
    Clin Liver Dis; 2004 Feb; 8(1):67-81, vi. PubMed ID: 15062194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cholestasis: therapeutic options].
    Beuers U; Oswald M
    Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cholestatic liver diseases].
    Reichel C; Meier-Abt PJ
    Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
    Beuers U; Bilzer M; Chittattu A; Kullak-Ublick GA; Keppler D; Paumgartner G; Dombrowski F
    Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
    Stiehl A
    Z Gastroenterol; 1992 Oct; 30(10):743-7. PubMed ID: 1441678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
    Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver.
    Wimmer R; Hohenester S; Pusl T; Denk GU; Rust C; Beuers U
    Gut; 2008 Oct; 57(10):1448-54. PubMed ID: 18583398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ursodeoxycholic acid: history and clinical implications].
    Beuers U; Trampert DC
    Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
    Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
    Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
    Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
    Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
    Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
    Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid therapy in children with cholestatic liver disease.
    Dinler G; Koçak N; Yüce A; Gürakan F; Ozen H
    Turk J Pediatr; 1999; 41(1):91-8. PubMed ID: 10770681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.